ICIs With Chemotherapy or Anti-Angiogenics for NSCLC ICIs With Chemotherapy or Anti-Angiogenics for NSCLC
Is immune checkpoint inhibitor combination therapy a safe and effective second-line treatment option for advanced non-small cell lung cancer patients?Translational Lung Cancer Research
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Hematology | Lung Cancer | Non-Small Cell Lung Cancer